Erratum to 'Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma' [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101644]

Andreas Obermair¹, Val Gebski², Jeffrey Goh³, Anna Kuchel⁴, Alison Brand⁵, Blossom Mak⁶, Orla McNally⁷, Eva Baxter⁸, Thomas Jobling⁹, Linda Mileshkin¹⁰

Affiliations

¹ Royal Brisbane and Women's Hospital Campus, UQ Centre for Clinical Research, The University of Queensland, Queensland Centre for Gynaecological Cancer (QCGC) Research, Herston, QLD, Australia. Electronic address: a.obermair@uq.edu.au.
² The University of Sydney, Faculty of Medicine and Health, NHMRC Clinical Trials Centre, Camperdown, NSW, Australia.
³ Cancer Care Services, Royal Brisbane and Women's Hospital, Herston, QLD, Australia.
⁴ Cancer Care Services, Royal Brisbane and Women's Hospital, Herston, QLD, Australia; University of Queensland, The School of Medicine, Herston, QLD, Australia.
⁵ Westmead Hospital, The Crown Princess Mary Cancer Centre, Westmead, NSW, Australia; Westmead Centre for Gynaecological Oncology, The University of Sydney, Camperdown, NSW, Australia.
⁶ The University of Sydney, Faculty of Medicine and Health, NHMRC Clinical Trials Centre, Camperdown, NSW, Australia; Westmead Hospital, The Crown Princess Mary Cancer Centre, Westmead, NSW, Australia.
⁷ Oncology and Dysplasia Service, The Royal Women's Hospital, Parkville, VIC, Australia; Department of Obstetrics and Gynaecology, The University of Melbourne, Parkville, VIC, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
⁸ Royal Brisbane and Women's Hospital Campus, UQ Centre for Clinical Research, The University of Queensland, Queensland Centre for Gynaecological Cancer (QCGC) Research, Herston, QLD, Australia.
⁹ Monash University, Department of Obstetrics and Gynaecology, Clayton, VIC, Australia; Monash Health, Women's and Newborn Program, Clayton, VIC, Australia.
¹⁰ Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

PMID: 40506308
DOI: 10.1016/j.ijgc.2025.101961

Published Erratum

Erratum to 'Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma' [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101644]

Andreas Obermair et al. Int J Gynecol Cancer. 2025 Sep.

. 2025 Sep;35(9):101961.

doi: 10.1016/j.ijgc.2025.101961. Epub 2025 Jun 11.

Authors

Andreas Obermair¹, Val Gebski², Jeffrey Goh³, Anna Kuchel⁴, Alison Brand⁵, Blossom Mak⁶, Orla McNally⁷, Eva Baxter⁸, Thomas Jobling⁹, Linda Mileshkin¹⁰

Affiliations

¹ Royal Brisbane and Women's Hospital Campus, UQ Centre for Clinical Research, The University of Queensland, Queensland Centre for Gynaecological Cancer (QCGC) Research, Herston, QLD, Australia. Electronic address: a.obermair@uq.edu.au.
² The University of Sydney, Faculty of Medicine and Health, NHMRC Clinical Trials Centre, Camperdown, NSW, Australia.
³ Cancer Care Services, Royal Brisbane and Women's Hospital, Herston, QLD, Australia.
⁴ Cancer Care Services, Royal Brisbane and Women's Hospital, Herston, QLD, Australia; University of Queensland, The School of Medicine, Herston, QLD, Australia.
⁵ Westmead Hospital, The Crown Princess Mary Cancer Centre, Westmead, NSW, Australia; Westmead Centre for Gynaecological Oncology, The University of Sydney, Camperdown, NSW, Australia.
⁶ The University of Sydney, Faculty of Medicine and Health, NHMRC Clinical Trials Centre, Camperdown, NSW, Australia; Westmead Hospital, The Crown Princess Mary Cancer Centre, Westmead, NSW, Australia.
⁷ Oncology and Dysplasia Service, The Royal Women's Hospital, Parkville, VIC, Australia; Department of Obstetrics and Gynaecology, The University of Melbourne, Parkville, VIC, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
⁸ Royal Brisbane and Women's Hospital Campus, UQ Centre for Clinical Research, The University of Queensland, Queensland Centre for Gynaecological Cancer (QCGC) Research, Herston, QLD, Australia.
⁹ Monash University, Department of Obstetrics and Gynaecology, Clayton, VIC, Australia; Monash Health, Women's and Newborn Program, Clayton, VIC, Australia.
¹⁰ Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

PMID: 40506308
DOI: 10.1016/j.ijgc.2025.101961

No abstract available

PubMed Disclaimer

Erratum for

Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma.
Obermair A, Gebski V, Goh J, Kuchel A, Brand A, Mak B, McNally O, Baxter E, Jobling T, Mileshkin L. Obermair A, et al. Int J Gynecol Cancer. 2025 Apr;35(4):101644. doi: 10.1016/j.ijgc.2025.101644. Epub 2025 Jan 16. Int J Gynecol Cancer. 2025. PMID: 39955187

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Erratum to 'Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma' [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101644]

Affiliations

Erratum to 'Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma' [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101644]

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources